Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why the FDA Extended Review Date on Key Melanoma Drug Opdivo
Why the FDA Extended Review Date on Key Melanoma Drug Opdivo
Why the FDA Extended Review Date on Key Melanoma Drug Opdivo
Submitted by
admin
on August 13, 2015 - 8:43am
Source:
24/7 Wall St
News Tags:
melanoma
FDA
Opdivo
Bristol-Myers Squibb
Headline:
Why the FDA Extended Review Date on Key Melanoma Drug Opdivo
Do Not Allow Advertisers to Use My Personal information
